{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:37:24Z","timestamp":1762079844002,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.transproceed.2022.08.027","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T01:55:35Z","timestamp":1664589335000},"page":"2317-2324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Everolimus Use in Lung Transplant Recipients"],"prefix":"10.1016","volume":"54","author":[{"given":"Sinan","family":"Turkkan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatmanur Celik","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Furkan","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet Ali","family":"Beyoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fclya Yigit","family":"Ozay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Bindal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alkin","family":"Yazicioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdal","family":"Yekeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2022.08.027_bib0001","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.healun.2017.07.016","article-title":"The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time","volume":"36","author":"Chambers","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13063-020-04843-9","article-title":"Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation","volume":"22","author":"Benazzo","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0003","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0004","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00228-010-0902-6","article-title":"Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials","volume":"66","author":"Penninga","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0005","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.transproceed.2015.08.043","article-title":"Incidence and long-term prognosis of cancer after kidney transplantation","volume":"47","author":"Pend\u00f3n-Ruiz de Mier","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1517\/17425255.2012.726219","article-title":"Proliferation signal inhibitor toxicities after thoracic transplantation","volume":"9","author":"Ensor","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0007","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.transproceed.2019.12.011","article-title":"Descriptive analysis of everolimus conversion in liver transplant recipients with malignant neoplastic disease","volume":"52","author":"Nogueras L\u00f3pez","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0008","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.arbres.2017.04.001","article-title":"Kaposi sarcoma and lung transplant: two case reports","volume":"53","author":"Meira","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0009","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.healun.2011.01.714","article-title":"Five-year outcomes with alemtuzumab induction after lung transplantation","volume":"30","author":"Shyu","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210443","article-title":"Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: a single centre experience","volume":"14","author":"Benazzo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0011","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/ajt.12824","article-title":"Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study","volume":"14","author":"Jaksch","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0012","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1016\/j.transproceed.2018.08.044","article-title":"Acute cellular rejection and infection rates in alemtuzumab vs traditional induction therapy agents for lung and heart transplantation: a systematic review and meta-analysis","volume":"50","author":"Li","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0013","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match","volume":"38","author":"Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0014","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1183\/09031936.00107514","article-title":"An international ISHLT\/ATS\/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome","volume":"44","author":"Meyer","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","article-title":"Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the Pulmonary Council of the ISHLT","volume":"38","author":"Verleden","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0016","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5414\/CN109287","article-title":"Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: a systematic review and meta-analysis","volume":"89","author":"He","year":"2018","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0017","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s11255-014-0783-1","article-title":"Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis","volume":"46","author":"Su","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0018","article-title":"Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: a meta-analysis of randomized controlled trials","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0019","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0020","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ctr.12353","article-title":"Renal function preservation with the mTOR inhibitor, everolimus, after lung transplant","volume":"28","author":"Schneer","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/2040622321993441","article-title":"Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes","volume":"12","author":"Patrucco","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0022","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.amjms.2016.08.014","article-title":"Targeting the mammalian target of rapamycin in lung cancer","volume":"352","author":"Vicary","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4369574","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.transproceed.2009.11.017","article-title":"Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies","volume":"42","author":"Chiurchiu","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0026","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.transproceed.2009.06.040","article-title":"Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation","volume":"41","author":"Gonz\u00e1lez","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7089482","article-title":"Risk factors for developing nonmelanoma skin cancer after lung transplantation","volume":"2019","author":"Grager","year":"2019","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0028","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/430209","article-title":"Posttransplant lymphoproliferative disease after lung transplantation","volume":"2013","author":"Neuringer","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0029","doi-asserted-by":"crossref","first-page":"537","DOI":"10.6002\/ect.2019.0246","article-title":"Rapidly progressive pulmonary Kaposi sarcoma after bilateral sequential lung transplant: a case report","volume":"20","author":"Turkkan","year":"2022","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1053-2498(02)00446-1","article-title":"Management of lung transplant recipients with bronchogenic carcinoma in the native lung","volume":"22","author":"de Perrot","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0031","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.transproceed.2004.10.014","article-title":"Incidence of primary neoplasms in explanted lungs: long-term follow-up from 214 lung transplant patients","volume":"36","author":"Abrahams","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0032","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2214\/AJR.12.9374","article-title":"Malignancies incidentally detected at lung transplantation: radiologic and pathologic features","volume":"201","author":"Strollo","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0033","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/ctr.12764","article-title":"Lung transplantation in patients with incidental early stage lung cancer-institutional experience of a high volume center","volume":"30","author":"Klikovits","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0034","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.athoracsur.2018.09.022","article-title":"Patterns of recurrence and overall survival in incidental lung cancer in explanted lungs","volume":"107","author":"Ahmad","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.athoracsur.2013.07.072","article-title":"Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients","volume":"97","author":"Sacher","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0036","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM Study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0037","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0038","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Jr","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0039","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from month 3: a multicentre, randomized trial","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0040","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0041","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/TP.0b013e3181fd01b7","article-title":"Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial","volume":"90","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.08.027_bib0042","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.transproceed.2007.06.048","article-title":"mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study","volume":"39","author":"Moro","year":"2007","journal-title":"Transplant Proc"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134522005693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134522005693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:45:26Z","timestamp":1758577526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134522005693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0041134522005693"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2022.08.027","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus Use in Lung Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2022.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}